Nectin-4 Tumor Expression as a Prognostic Factor and Potential Therapeutic Target in Stage II/III Rectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Rectal cancer (RC) incidence is rising globally, accounting for a third of colorectal cancers.
• Nectin-4 shows oncogenic potential in various cancers, but its role in RC is unclear.
• Understanding Nectin-4's mechanism is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the prognostic significance of Nectin-4 in localized advanced rectal cancer.
• To elucidate the underlying mechanisms of Nectin-4 in rectal cancer cell proliferation.
• To evaluate Nectin-4 as a potential therapeutic target for rectal cancer.

Main Methods:

• Immunohistochemistry was used to assess Nectin-4 expression in 135 RC tissue samples (Stage II/III).
• Survival analysis (overall survival, recurrence-free survival) and multivariate analysis were performed.
• In-vitro assays, including Nectin-4 silencing via siRNA and combination therapy with 5-FU, were conducted.

Main Results:

• High Nectin-4 expression correlated with significantly worse postoperative prognosis (OS: P=0.002, RFS: P=0.002).
• Nectin-4 was identified as an independent prognostic factor for RC (OS: P=0.002, RFS: P=0.002).
• Nectin-4 silencing inhibited RC cell proliferation, and its combination with 5-FU showed synergistic antitumor effects.

Conclusions:

• Nectin-4 expression is a significant prognostic biomarker in rectal cancer.
• Nectin-4 plays a crucial role in rectal cancer cell proliferation and progression.
• Targeting Nectin-4 offers a promising strategy for novel, individualized rectal cancer therapies and precision medicine.